Grown Rogue International (GRUSF) Amortizatization of Intangibles (2018 - 2026)
Grown Rogue International (GRUSF) posted quarterly Amortizatization of Intangibles of $42210.0 for Q1 2026, down 80.83% year-over-year from $220133.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$812.2 billion in Q4 2025.
Grown Rogue International (GRUSF) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Grown Rogue International's Amortizatization of Intangibles history runs 9 years deep, the most recent figure standing at $42210.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 80.83% year-over-year to $42210.0; the TTM figure through Mar 2026 stood at -$177923.0 (down 110.62% YoY), while the FY2024 annual figure was $1.8 million, up 748.27% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $42210.0, up from -$812.2 billion in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $1531.6 billion in Q3 2024, with the low at -$1531.5 billion in Q4 2024.
- The 5-year median for Amortizatization of Intangibles is $294195.5 (2025), against an average of $263617.2.
- The sharpest annual moves came in 2025 and 2026: Amortizatization of Intangibles surged 46.97% in 2025, then slumped 80.83% in 2026.
- Grown Rogue International's Amortizatization of Intangibles stood at $151685.0 in 2022, then surged by 468.69% to $862624.0 in 2023, then plunged by 177545492.15% to -$1531.5 billion in 2024, then soared by 46.97% to -$812.2 billion in 2025, then surged by 100.0% to $42210.0 in 2026.
- Business Quant data shows GRUSF's Amortizatization of Intangibles at $42210.0 in Q1 2026, -$812.2 billion in Q4 2025, and $812.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 900,000.00 |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Grown Rogue International | 109.32 Mn | 97.78 Mn | 5.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42,210.00 |
| Mar 31, 2026 | 42,210.00 |
| Dec 31, 2025 | -812.21 Bn |
| Dec 31, 2025 | -812.21 Bn |
| Sep 30, 2025 | 812.21 Bn |
| Sep 30, 2025 | 812.21 Bn |
| Jun 30, 2025 | 368,258.00 |
| Jun 30, 2025 | 368,258.00 |
| Mar 31, 2025 | 220,133.00 |
| Mar 31, 2025 | 220,133.00 |
| Dec 31, 2024 | -1,531.55 Bn |
| Dec 31, 2024 | -1,531.55 Bn |
| Sep 30, 2024 | 1,531.55 Bn |
| Sep 30, 2024 | 1,531.55 Bn |
| Jun 30, 2024 | 378,404.00 |
| Jun 30, 2024 | 378,404.00 |
| Mar 31, 2024 | 381,663.00 |
| Mar 31, 2024 | 381,663.00 |
| Oct 31, 2023 | 862,624.00 |
| Oct 31, 2023 | 862,624.00 |